莲花健康(600186) - 2021 Q3 - 季度财报
LHGLHG(SH:600186)2021-10-29 16:00

Financial Performance - The company's operating revenue for Q3 2021 was ¥478,856,367.20, representing a year-over-year increase of 12.14%[5] - The net profit attributable to shareholders for Q3 2021 was ¥8,136,005.89, a decrease of 61.63% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥8,728,752.83, down 54.94% year-over-year[5] - Basic earnings per share for Q3 2021 were ¥0.0085, a decline of 44.71% compared to the previous year[7] - The diluted earnings per share for Q3 2021 were also ¥0.0085, reflecting a 44.71% decrease year-over-year[7] - The weighted average return on equity for Q3 2021 was 0.90%, a decrease of 5.11 percentage points from the previous year[7] - Total operating revenue for the first three quarters of 2021 reached ¥1,329,473,254.17, an increase from ¥1,209,529,582.00 in the same period of 2020, representing a growth of approximately 9.9%[29] - The net profit attributable to shareholders of the parent company for Q3 2021 was ¥36,703,879.66, compared to ¥52,333,114.38 in Q3 2020, reflecting a decrease of approximately 30%[32] - Total comprehensive income amounted to CNY 37,789,530.07 for the current period, compared to CNY 54,674,834.86 in the previous period, reflecting a decrease of approximately 30.8%[34] - Basic and diluted earnings per share were CNY 0.0252, down from CNY 0.0379 in the previous period, indicating a decline of about 33.5%[34] Assets and Liabilities - Total assets at the end of Q3 2021 amounted to ¥2,254,284,037.45, an increase of 49.91% compared to the end of the previous year[7] - The company's total assets as of September 30, 2021, amounted to approximately RMB 2.25 billion, an increase from RMB 1.50 billion at the end of 2020[20] - The company's total liabilities decreased to ¥1,089,335,794.80 in Q3 2021 from ¥1,352,823,471.80 in Q3 2020, a reduction of about 19.5%[29] - The equity attributable to shareholders at the end of Q3 2021 was ¥1,398,169,283.11, up 262.87% from the previous year[7] - The total equity attributable to shareholders of the parent company increased to ¥1,398,169,283.11 in Q3 2021 from ¥385,307,198.86 in Q3 2020, showing a significant increase of approximately 263%[29] Cash Flow - The company reported a cash flow from operating activities of ¥85,989,575.12 for the year-to-date period[5] - Cash inflow from operating activities totaled CNY 1,470,949,767.01, an increase from CNY 1,296,802,065.12, representing a growth of approximately 13.4%[38] - Cash outflow from operating activities decreased to CNY 1,384,960,191.89 from CNY 2,047,860,548.96, showing a reduction of about 32.3%[38] - Net cash flow from operating activities was CNY 85,989,575.12, a significant improvement compared to a net outflow of CNY -751,058,483.84 in the previous period[38] - Cash inflow from financing activities reached CNY 1,046,198,204.59, a substantial increase from CNY 50,450,000.00 in the previous period[39] - Net cash flow from financing activities was CNY 627,935,972.33, compared to a net outflow of CNY -215,359,217.35 in the previous period, indicating a turnaround[39] - The ending balance of cash and cash equivalents was CNY 702,205,776.24, a significant increase from CNY 40,397,350.87 in the previous period[39] - The company reported a cash inflow of CNY 8,252,635.25 from tax refunds, up from CNY 4,581,719.77 in the previous period, marking an increase of approximately 80.5%[38] - Cash outflow for employee compensation was CNY 95,132,059.91, a decrease from CNY 839,812,043.38 in the previous period, reflecting a reduction of about 88.7%[38] Shareholder Information - The total number of common shareholders at the end of the reporting period was 57,167[16] - The largest shareholder, Wuhu Liantai Investment Management Center, holds 180,509,529 shares, representing 10.06% of total shares[16] Operational Challenges - The increase in raw material procurement prices exceeded the increase in product sales prices, impacting the gross profit margin negatively[12] Research and Development - Research and development expenses for Q3 2021 were ¥9,636,221.63, a substantial increase from ¥1,275,219.95 in Q3 2020, representing a growth of about 655%[29] Future Outlook - The company plans to continue focusing on market expansion and new product development to drive future growth[30]